ORIGINAL PAPER
LncSLED1 inhibits monosodium urate-induced macrophage inflammation by promoting Cosmc methylation to upregulate CA72-4
1
Shandong Second Medical University, Weifang 261053, Shandong, China
2
Department of Endocrinology and Rheumatology, Rongcheng People’s Hospital, Weihai 264300, Shandong, China
3
Department of Endocrinology, Zibo Central Hospital, ZiBo 255020, Shandong, China
These authors had equal contribution to this work
Submission date: 2025-01-07
Final revision date: 2025-04-27
Acceptance date: 2025-05-27
Online publication date: 2026-02-09
KEYWORDS
ABSTRACT
Introduction:
The core event of gout is intensified macrophage inflammation. Our preliminary research found that carbohydrate antigen 72-4 (CA72-4) secreted by monosodium urate (MSU)-induced human synovial cells (HFLS) could upregulate transforming growth factor 1 (TGF-1) in macrophages. Herein, the mechanism of MSU-induced abnormal upregulation of CA72-4 in HFLS was investigated.
Material and Methods:
Cell viability was assessed by CCK-8 assay. The secretion levels of cytokines and CA72-4 were measured by ELISA. Methylation-specific PCR (MSP) was employed to detect the methylation level of the Cosmc promoter. The molecular interactions were analyzed by RIP and ChIP assays.
Results:
Our results demonstrated that CA72-4 derived from MSU-treated HFLS markedly inhibited MSU-induced macrophage inflammation. Mechanistically, MSU-induced lncSLED1 upregulation in HFLS reduced MSU-induced macrophage inflammation by promoting CA72-4 secretion. In addition, lncSLED1 facilitated CA72-4 secretion in MSU-treated HFLS by promoting the methylation level of the Cosmc promoter through recruiting EZH2. As expected, Cosmc silencing in HFLS reversed the weakening effect of lncSLED1 downregulation on mCM (the conventional medium from MSU-treated HFLS)-induced inhibition of MSU-induced macrophage inflammation.
Conclusions:
MSU elevated lncSLED1 in HFLS, boosting CA72-4 secretion by increasing Cosmc promoter methylation via EZH2 recruitment, thus reducing MSU-induced macrophage inflammation.
The core event of gout is intensified macrophage inflammation. Our preliminary research found that carbohydrate antigen 72-4 (CA72-4) secreted by monosodium urate (MSU)-induced human synovial cells (HFLS) could upregulate transforming growth factor 1 (TGF-1) in macrophages. Herein, the mechanism of MSU-induced abnormal upregulation of CA72-4 in HFLS was investigated.
Material and Methods:
Cell viability was assessed by CCK-8 assay. The secretion levels of cytokines and CA72-4 were measured by ELISA. Methylation-specific PCR (MSP) was employed to detect the methylation level of the Cosmc promoter. The molecular interactions were analyzed by RIP and ChIP assays.
Results:
Our results demonstrated that CA72-4 derived from MSU-treated HFLS markedly inhibited MSU-induced macrophage inflammation. Mechanistically, MSU-induced lncSLED1 upregulation in HFLS reduced MSU-induced macrophage inflammation by promoting CA72-4 secretion. In addition, lncSLED1 facilitated CA72-4 secretion in MSU-treated HFLS by promoting the methylation level of the Cosmc promoter through recruiting EZH2. As expected, Cosmc silencing in HFLS reversed the weakening effect of lncSLED1 downregulation on mCM (the conventional medium from MSU-treated HFLS)-induced inhibition of MSU-induced macrophage inflammation.
Conclusions:
MSU elevated lncSLED1 in HFLS, boosting CA72-4 secretion by increasing Cosmc promoter methylation via EZH2 recruitment, thus reducing MSU-induced macrophage inflammation.
REFERENCES (56)
1.
Duan L, Zhong J, Yang Y, et al. (2022): Editorial: Advances in pathogenesis and therapies of gout. Front Immunol 13: 890204.
2.
Zhu B, Wang Y, Zhou W, et al. (2022): Trend dynamics of gout prevalence among the Chinese population, 1990-2019: A joinpoint and age-period-cohort analysis. Front Public Health 10: 1008598.
3.
Kuo CF, Grainge MJ, Mallen C, et al. (2015): Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 74: 661-667.
4.
Dehlin M, Jacobsson L, Roddy E (2020): Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16: 380-390.
5.
Chen-Xu M, Yokose C, Rai S K, et al. (2019): Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol 71: 991-999.
6.
Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. (2014): Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 73: 177-182.
7.
Chandratre P, Roddy E, Clarson L, et al. (2013): Health-related quality of life in gout: a systematic review. Rheumatology (Oxford) 52: 2031-2040.
8.
Hall CJ, Sanderson LE, Lawrence LM, et al. (2018): Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation. J Clin Invest 128: 1752-1771.
9.
Richette P, Doherty M, Pascual E, et al. (2017): 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76: 29-42.
10.
FitzGerald JD, Dalbeth N, Mikuls T, et al. (2020): 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 72: 744-760.
11.
White WB, Saag KG, Becker MA, et al. (2018): Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378: 1200-1210.
12.
Liu L, Zhu L, Liu M, et al. (2022): Recent insights into the role of macrophages in acute gout. Front Immunol 13: 955806.
13.
Mei Y, Dong B, Geng Z, et al. (2022): Excess uric acid induces gouty nephropathy through crystal formation: A review of recent insights. Front Endocrinol (Lausanne) 13: 911968.
14.
Song JE, Kim JS, Shin JH, et al. (2021): Role of synovial exosomes in osteoclast differentiation in inflammatory arthritis. Cells 10: 120.
15.
Rajesh C, Radhakrishnan P (2022): The (Sialyl) Tn antigen: Contributions to immunosuppression in gastrointestinal cancers. Front Oncol 12: 1093496.
16.
Xu Y, Zhang P, Zhang K, et al. (2021): The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochim Biophys Acta Rev Cancer 1876: 188634.
17.
Mariampillai A I, Cruz J P D, Suh J, et al. (2017): Cancer antigen 72-4 for the monitoring of advanced tumors of the gastrointestinal tract, lung, breast and ovaries. Anticancer Res 37: 3649-3656.
18.
Hu S, Sun M, Li M, et al. (2023): Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford) 62: 2435-2443.
19.
Bai X, Sun M, He Y, et al. (2020): Serum CA72-4 is specifically elevated in gout patients and predicts flares. Rheumatology (Oxford) 59: 2872-2880.
20.
Hofmann BT, Schlüter L, Lange P, et al. (2015): COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer 14: 109.
21.
Ju T, Cummings RD (2002): A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A 99: 16613-16618.
22.
Ju T, Aryal RP, Kudelka MR, et al. (2014): The Cosmc connection to the Tn antigen in cancer. Cancer Biomark 14: 63-81.
23.
Gollamudi S, Lekhraj R, Lalezari S, et al. (2020): COSMC mutations reduce T-synthase activity in advanced Alzheimer’s disease. Alzheimers Dement (NY) 6: e12040.
24.
Emran AA, Chatterjee A, Rodger EJ, et al. (2019): Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol 40: 328-344.
25.
Shi C, Xu X, Yu X, et al. (2017): CD3/CD28 dynabeads induce expression of tn antigen in human t cells accompanied by hypermethylation of the cosmc promoter. Mol Immunol 90: 98-105.
26.
Mi R, Song L, Wang Y, et al. (2012): Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen. J Biol Chem 287: 41523-41533.
27.
Herman AB, Tsitsipatis D, Gorospe M (2022): Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell 82: 2252-2266.
28.
Mattick JS, Amaral PP, Carninci P, et al. (2023): Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol 24: 430-447.
29.
Statello L, Guo CJ, Chen LL, et al. (2021): Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 22: 96-118.
30.
Atianand MK, Hu W, Satpathy AT, et al. (2016): A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell 165: 1672-1685.
31.
Liu YF, Xing GL, Chen Z, et al. (2021): Long non-coding RNA HOTAIR knockdown alleviates gouty arthritis through miR-20b upregulation and NLRP3 downregulation. Cell Cycle 20: 332-344.
32.
Zhang X, Zou Y, Zheng J, et al. (2020): lncRNA MM2P downregulates the production of pro inflammatory cytokines in acute gouty arthritis. Mol Med Rep 22: 2227-2234.
33.
Qing YF, Zheng JX, Tang YP, et al. (2021): LncRNAs landscape in the patients of primary gout by microarray analysis. PLoS One 16: e0232918.
34.
Zhang C, Wang L, Jin C, et al. (2021): Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1. Cell Death Dis 12: 224.
35.
Chen TL, Lin YF, Cheng CW, et al. (2011): Anti-Inflammatory mechanisms of the proteinase-activated receptor 2-inhibiting peptide in human synovial cells. J Biomed Sci 18: 43.
36.
Akgul SU, Cinar CK, Caliskan Y, et al. (2023): COSMC expression as a predictor of remission in IgA nephropathy. Int Urol Nephrol 55: 1033-1044.
37.
Hattori N, Liu YY, Ushijima T (2023): DNA methylation analysis. Methods Mol Biol 2691: 165-183.
38.
Verma A, Singh A, Singh MP, et al. (2022): EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nat Commun 13: 7344.
39.
Lan Z, Chen L, Feng J, et al. (2021): Mechanosensitive TRPV4 is required for crystal-induced inflammation. Ann Rheum Dis 80: 1604-1614.
40.
Szekanecz E, Sándor Z, Antal-Szalmás P, et al. (2007): Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann N Y Acad Sci 1108: 359-371.
41.
Takamiya R, Ohtsubo K, Takamatsu S, et al. (2013): The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF- secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 23: 178-187.
42.
Zhang X, Liu J, Sun Y, et al. (2023): Chinese herbal compound Huangqin Qingrechubi capsule reduces lipid metabolism disorder and inflammatory response in gouty arthritis via the LncRNA H19/APN/PI3K/AKT cascade. Pharm Biol 61: 541-555.
43.
Ishii T, Onda H, Tanigawa A, et al. (2005): Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res 12: 429-39.
44.
Xu F, Wang D, Cui J, et al. (2020): Demethylation of the Cosmc promoter alleviates the progression of breast cancer through downregulation of the Tn and Sialyl-Tn antigens. Cancer Manag Res 12: 1017-1027.
45.
Li DQ, Ding YR, Che JH, et al. (2022): Tumor suppressive lncRNA MEG3 binds to EZH2 and enhances CXCL3 methylation in gallbladder cancer. Neoplasma 69: 538-549.
46.
Duan R, Du W, Guo W (2020): EZH2: a novel target for cancer treatment. J Hematol Oncol 13: 104.
47.
Dimopoulos K, Søgaard Helbo A, Fibiger Munch-Petersen H, et al. (2018): Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol 12: 180-195.
48.
Gabay C, Lamacchia C, Palmer G (2010): IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6: 232-241.
49.
Zhao B, Zhang M, Liang Y, et al. (2019): An abnormal elevation of serum CA72-4 rather than other tumor markers can be caused by use of colchicine. Int J Biol Markers 34: 318-321.
50.
Burmester GR, Blanco R, Charles-Schoeman C, et al. (2013): Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381: 451-460.
51.
Shi L, Yuan Z, Liu J, et al. (2021): Modified Simiaowan prevents articular cartilage injury in experimental gouty arthritis by negative regulation of STAT3 pathway. J Ethnopharmacol 270: 113825.
52.
Wu H, Wang Y, Huang J, et al. (2023): Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail. Biomed Pharmacother 158: 114175.
53.
Thompson CL, Hopkins T, Bevan C, et al. (2023): Human vascularised synovium-on-a-chip: a mechanically stimulated, microfluidic model to investigate synovial inflammation and monocyte recruitment. Biomed Mater 18.
54.
Hao K, Jiang W, Zhou M, et al. (2020): Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis. Int J Biol Sci 16: 3163-3173.
55.
Cheng JJ, Ma XD, Ai GX, et al. (2022): Palmatine protects against MSU-induced gouty arthritis via regulating the NF-B/NLRP3 and Nrf2 pathways. Drug Des Devel Ther 16: 2119-2132.
56.
Wang G, Liu Z, Zheng Y, et al. (2024): Transcriptomic analysis of THP-1 cells exposed by monosodium urate reveals key genes involved in gout. Comb Chem High Throughput Screen 27: 2741-2752.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
